GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » Total Receivables

Macrogenics (FRA:M55) Total Receivables : €7.9 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Total Receivables?

Macrogenics's Total Receivables for the quarter that ended in Sep. 2024 was €7.9 Mil.


Macrogenics Total Receivables Historical Data

The historical data trend for Macrogenics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Total Receivables Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.47 18.97 9.19 53.07 9.51

Macrogenics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.72 9.51 6.64 5.75 7.88

Macrogenics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Macrogenics Total Receivables Related Terms

Thank you for viewing the detailed overview of Macrogenics's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Macrogenics Headlines

No Headlines